Portia M Gillespie (Portia Gillespie)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 3

Top Venues

Human vaccines & immunotherapeutics

Vaccines

This page only lists publications with an associated author ORCID identifier.

Publications

Syamala Rani Thimmiraju, Rakesh Adhikari, Maria Jose Villar, Jungsoon Lee, Zhuyun Liu, Rakhi Kundu, Yi-Lin Chen, Suman Sharma, Karm Ghei, Brian Keegan, Leroy Versteeg, Portia M Gillespie, Allan Ciciriello, Nelufa Y Islam, Cristina Poveda, Nestor Uzcategui, Wen-Hsiang Chen, Jason T Kimata, Bin Zhan, Ulrich Strych, Maria-Elena Bottazzi, Peter J Hotez, Jeroen Pollet
A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2. Vaccines 11 (10) (2023)
Jeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, Brian Keegan, Bin Zhan, Junfei Wei, Zhuyun Liu, Jungsoon Lee, Rahki Kundu, Rakesh Adhikari, Cristina Poveda, Maria Jose Villar, Ana Carolina de Araujo Leao, Joanne Altieri Rivera, Zoha Momin, Portia M Gillespie, Jason T Kimata, Ulrich Strych, Peter Jay Hotez, Maria Elena Bottazzi
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Human vaccines & immunotherapeutics 17 (8) (2021)
Juan Jose de la Cruz, Liliana Villanueva-Lizama, Victor Dzul-Huchim, María-Jesus Ramírez-Sierra, Pedro Martinez-Vega, Miguel Rosado-Vallado, Jaime Ortega-Lopez, Claudia Ivonne Flores-Pucheta, Portia M Gillespie, Bin Zhan, Maria Elena Bottazzi, Peter Jay Hotez, Eric Dumonteil
Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice. Human vaccines & immunotherapeutics 15 (1) (2018)

Portia M Gillespie.css-eqlu8i{font-size:small;padding-left:4px;} (Portia Gillespie)

Publication Activity (10 Years)

Top Topics

Top Venues

Portia M Gillespie (Portia Gillespie)